Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Scientific Advisory Board

Elizabeth P. Rakoczy, Ph.D.

Dr. Rakoczy is the Winthrop Professor of Molecular Ophthalmology at the Lions Eye Institute, University of Western Australia, and has pioneered work in gene therapy for ocular neovascular disease.

Jean E. Bennett, M.D., Ph.D.

Dr. Bennett is the F.M. Kirby Professor of Ophthalmology at the University of Pennsylvania and is a renowned expert in gene therapy, animal models, and translational medicine in retinal disease.

Estuardo Aguilar-Cordova, M.D., Ph.D.

Dr. Aguilar-Cordova is the Chief Executive Officer, Advantagene, and a recognized expert in regulatory affairs and product development in both academic and biotechnology settings.

Thomas W. Chalberg, Jr., PhD

Dr. Chalberg is a founder of Avalanche Biotechnologies and brings many years of experience in ophthalmology research and development and commercialization to the Board.

Mitchell H. Finer, Ph.D.

Dr. Finer is a founder and Distinguished Research Fellow of Avalanche Biotechnologies. Dr. Finer was most recently the Chief Scientific Officer of bluebird bio. He has over 25 years of experience in biotechnology product development.

Daniel V. Palanker, Ph.D.

Dr. Palanker is the Associate Professor in the Department of Ophthalmology and in Hansen Experimental Physics Laboratory at Stanford University. He is an expert in ophthalmic lasers and in interactions of pulsed electric field and light with biological cells and tissues.

The results of a Phase 1, 52-week trial of Avalanche Biotechnologies’ rAAV.sFLT-1 (AVA-101) gene therapy for the treatment of wet age-related macular degeneration (wAMD) have been published online by The Lancet. The study sought to evaluate the safety of rAAV.sFLT-1 via a single subretinal injection. Results of the study demonstrate that rAAV.sFLT-1 was safe and well tolerated, and support ocular gene therapy as a potential long-term treatment option for wAMD.

“The use of gene therapy to reprogramme genetically normal cells of the retina to take on additional functions opens a new chapter in potential AAV applications.”
– Dr. Robert MacLaren, Moorsfield Eye Hospital

The complete article and editorial commentary by Dr. MacLaren, are available from The Lancet.

Read All Avalanche News